Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
Total Valuation
TG Therapeutics has a market cap or net worth of $4.59B. The enterprise value is $4.78B.
Market Cap$4.59B
Enterprise Value$4.78B
Share Statistics
TG Therapeutics has 159,688,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding159,688,260
Owned by Insiders7.23%
Owned by Institutions11.32%
Financial Efficiency
TG Therapeutics’s return on equity (ROE) is 0.69 and return on invested capital (ROIC) is 13.54%.
Return on Equity (ROE)0.69
Return on Assets (ROA)0.42
Return on Invested Capital (ROIC)13.54%
Return on Capital Employed (ROCE)0.14
Revenue Per Employee1.75M
Profits Per Employee1.27M
Employee Count352
Asset Turnover0.58
Inventory Turnover0.80
Valuation Ratios
The current PE Ratio of TG Therapeutics is 9.6. TG Therapeutics’s PEG ratio is 0.00524.
PE Ratio9.6
PS Ratio6.98
PB Ratio6.64
Price to Fair Value6.64
Price to FCF-172.18
Price to Operating Cash Flow-166.03
PEG Ratio0.00524
Income Statement
In the last 12 months, TG Therapeutics had revenue of 616.29M and earned 447.18M in profits. Earnings per share was 3.10.
Revenue616.29M
Gross Profit515.33M
Operating Income123.32M
Pretax Income107.39M
Net Income447.18M
EBITDA134.36M
Earnings Per Share (EPS)3.10
Cash Flow
In the last 12 months, operating cash flow was -24.77M and capital expenditures -214.00K, giving a free cash flow of -24.99M billion.
Operating Cash Flow-24.77M
Free Cash Flow-24.99M
Free Cash Flow per Share-0.16
Dividends & Yields
TG Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.69
52-Week Price Change-29.93%
50-Day Moving Average29.50
200-Day Moving Average32.44
Relative Strength Index (RSI)47.67
Average Volume (3m)1.60M
Important Dates
TG Therapeutics upcoming earnings date is May 11, 2026, TBA (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date―
Financial Position
TG Therapeutics as a current ratio of 4.10, with Debt / Equity ratio of 40.24%
Current Ratio4.10
Quick Ratio3.29
Debt to Market Cap0.06
Net Debt to EBITDA1.35
Interest Coverage Ratio4.61
Taxes
In the past 12 months, TG Therapeutics has paid -339.79M in taxes.
Income Tax-339.79M
Effective Tax Rate-3.16
Enterprise Valuation
TG Therapeutics EV to EBITDA ratio is 33.37, with an EV/FCF ratio of -179.45.
EV to Sales7.28
EV to EBITDA33.37
EV to Free Cash Flow-179.45
EV to Operating Cash Flow-181.00
Balance Sheet
TG Therapeutics has $141.97M in cash and marketable securities with $260.73M in debt, giving a net cash position of -$118.76M billion.
Cash & Marketable Securities$141.97M
Total Debt$260.73M
Net Cash-$118.76M
Net Cash Per Share-$0.74
Tangible Book Value Per Share$4.49
Margins
Gross margin is 83.64%, with operating margin of 20.01%, and net profit margin of 72.56%.
Gross Margin83.64%
Operating Margin20.01%
Pretax Margin17.43%
Net Profit Margin72.56%
EBITDA Margin21.80%
EBIT Margin21.76%
Analyst Forecast
The average price target for TG Therapeutics is $42.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$42.00
Price Target Upside45.99% Upside
Analyst ConsensusModerate Buy
Analyst Count5
Revenue Growth Forecast100.88%
EPS Growth Forecast―